{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-103661","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.930206+00:00","generated_at":"2026-05-17T01:25:07.738754+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31","bullets":["Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.","Company has appealed to Nasdaq Listing and Hearing Review Council; also seeks OTC Markets trading.","$4.75M Series E Preferred financing contingent on Nasdaq listing; funding now uncertain.","Early clinical data for CER-1236 in three AML patients shows rapid cell expansion and no toxicity.","Company reviewing cash resources and financing alternatives; no assurance of funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-103661","json":"https://secwatch.observer/filing/0001213900-25-103661.json","markdown":"https://secwatch.observer/filing/0001213900-25-103661.md","text":"https://secwatch.observer/filing/0001213900-25-103661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/0001213900-25-103661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/ea0263036-8k_cerothera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:25:07.738754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"323f38dd672d0083a3e90a0d7e877b513ee1a9ef","claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued listing of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31, 2025. The Company has submitted a request for review of the Hearings Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “ Council ”). The Company has also commenced the process of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review by the Counci","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/0001213900-25-103661-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}